All In Biotech

Drug Trial Radar · NCT07152639

Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above

Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC) for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above

Last checked: Nov 19, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,784 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,784

Planned (sponsor's estimate)

Start

Aug 9, 2025

Primary completion

May 1, 2026

Study completion Jul 1, 2026

Sponsor

Lead sponsor
Chengdu CoenBiotech Co., LtdIndustry
Sponsor type
Industry
Collaborators
Beijing Chest Hospital, Capital Medical University; Wuhan Pulmonary Hospital; Changsha Central Hospital; The First Affiliated Hospital of Xinxiang Medical College; LiuZhou People's Hospital; Wuhan Central Hospital; Yichang Central People's Hospital
First posted
Sep 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 3 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a randomized, blinded, active-controlled clinical trial to evaluate the effectiveness and safety of EEC in the diagnosis of Mycobacterium tuberculosis infection in people aged 3 years and above. Methods: In study 1, the marketed recombinant Mycobacterium tuberculosis fusion protein (EC) was used as a control drug in people aged 3 to 64 years. The sensitivity of EEC in participants with tuberculosis and the specificity in healthy participants and patients with non-tuberculous lung diseases were evaluated compared with recombinant Mycobacterium tuberculosis fusion protein (EC). The clinical positivity criteria of EEC were verified, and the consistency of the two detection methods, as well as the safety of EEC, were evaluated. Study 2: Triple-negative people aged 18 and above (negative in EEC, TB-PPD, and IGRA tests) were screened out from the community population and vaccinated with BCG. EEC and TB-PPD double-arm skin tests were performed 12 weeks after vaccination to evaluate whether there was a significant difference in the negative rate of EEC compared with TB-PPD after BCG vaccination in the triple-negative population. Study 3: A multicenter, positive-controlled, non-inferiority trial design was used for people aged 65 years and above, and the research hypothesis was independently tested to verify the non-inferiority of the sensitivity of this product in tuberculosis patients in this age group compared with IGRA and TB-PPD, as well as the consistency of the diagnostic results of IGRA with non-tuberculous lung diseases and the general community population. At the same time, attention was paid to and analysis of the specificity and safety of EEC in people aged 65 years and above.

Conditions

  • Tuberculosis

Interventions

  • 5μg/ml EECBiological

    0.1ml, one time, containing high dose 5μg/ml of active ingredients

  • 5 unit(U) ECBiological

    0.1 ml , one time, containing 5U of active ingredients

  • 5 IU TB-PPDBiological

    0.1 ml , one time, containing 5IU of active ingredients

  • IGRADiagnostic test

    96-well/plate x 2 plates; 100 tubes/box x 1 box

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity (true positive rate) of EEC and EC detection methods in tuberculosis patients aged 3 to 64 yearsTime frame: 7 days after injection
  2. Specificity (true negative rate) of EEC and EC detection methods in patients with non-tuberculous lung diseases aged 3 to 64 yearsTime frame: 7 days after injection
  3. Specificity (true negative rate) of EEC and EC for the diagnosis of Mycobacterium tuberculosis infection in healthy participants aged 3-64 years .Time frame: 7 days after injection
  4. Negative rate of EEC test drug and TB-PPD control drug in BCG-vaccinated population in triple-negative populationTime frame: 7 days after second injection
  5. Sensitivity (true positive rate) of EEC test drug versus control IGRA and TB-PPD for assisting clinical diagnosis of tuberculosis in people aged 65 years and older with tuberculosisTime frame: 7 days after injection
  6. To evaluate the consistency (accordance rate) of the diagnostic results of EEC and IGRA in non-tuberculous lung diseases in the general community population aged 65 years and aboveTime frame: 7 days after injection

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chest Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Changsha Center Hospital

    Hunan, Changsha, China · Recruiting

  • LiuZhou People's Hospital

    Liuzhou, Guangxi, China · Recruiting

  • The First Affiliated Hospital of Xinxiang Medical College

    Xinxiang, Henan, China · Not yet recruiting

  • Wuhan Pulmonary Hospital

    Wuhan, Hubei, China · Recruiting

  • Wuhan Central Hospital

    Wuhan, Hubei, China · Recruiting

  • Yichang Central People's Hospital

    Yichang, Hubei, China · Recruiting

  • Public health clinical center of chengdu

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.